GlassScriptPhysician profile
Crystal Goins
NPI 1750971628
$6,645.73
in general payments reported to CMS, 2019-2025
50 companies · $1,703 in 2025
The $1,703 reported for 2025 was more than what 94% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $436 · 2022: $1,466 · 2023: $1,619 · 2024: $1,421 · 2025: $1,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,539 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,539.08 |
| Education | $204.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $724.33 | 2021-2025 | Enhertu, Injectafer, Vanflyta |
| Merck Sharp & Dohme LLC | $539.35 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $500.15 | 2022-2024 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $439.90 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $341.19 | 2021-2025 | Ninlaro, Iclusig, Fruzaqla |
| Janssen Biotech, INC. | $274.24 | 2022-2025 | Darzalex, Talvey, Erleada |
| Amgen INC. | $250.98 | 2021-2022 | |
| Pfizer INC. | $242.41 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $194.95 | 2021-2022 | |
| Genmab U.S., INC. | $188.67 | 2023-2025 | Tivdak |
| Eisai INC. | $171.53 | 2021-2025 | |
| Sobi, INC | $162.93 | 2024-2025 | |
| Genzyme Corporation | $161.50 | 2021-2025 | |
| Lilly USA, LLC | $136.64 | 2022 | |
| Beigene USA, INC. | $134.88 | 2022-2024 | Brukinsa |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $129.82 | 2022-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $125.25 | 2022-2025 | Ojjaara |
| Astrazeneca Pharmaceuticals LP | $123.28 | 2022-2024 | Calquence |
| Pharmacosmos Therapeutics INC. | $116.78 | 2023-2025 | Monoferric |
| Shield Therapeutics INC | $115.90 | 2024 | |
| Incyte Corporation | $113.55 | 2022-2024 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $112.91 | 2022-2025 | Libtayo |
| Gilead Sciences, INC. | $111.87 | 2023-2025 | Trodelvy |
| Array Biopharma INC | $88.61 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Taiho Oncology, INC. | $87.37 | 2023-2024 | |
| Organon LLC | $85.51 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $83.27 | 2021-2023 | Ultomiris |
| Tersera Therapeutics LLC | $82.13 | 2021-2025 | Zoladex, Xermelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.43 | 2022-2024 | Gilotrif |
| Puma Biotechnology, INC. | $62.81 | 2023-2024 | Nerlynx |
| Seagen INC. | $56.11 | 2022-2023 | Tukysa, Adcetris |
| Emd Serono, INC. | $55.22 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.39 | 2025 | |
| Pharmaessentia USA Corporation | $49.33 | 2024-2025 | Besremi |
| Boston Scientific Corporation | $48.37 | 2024 | Spaceoar Vue System - 10ml |
| Ipsen Biopharmaceuticals, INC | $47.33 | 2025 | Onivyde |
| Genentech USA, INC. | $41.46 | 2021-2022 | |
| Astellas Pharma US INC | $40.17 | 2025 | Xospata, Cresemba |
| E.R. Squibb & Sons, L.L.C. | $38.26 | 2022-2025 | Opdualag |
| Myovant Sciences INC. | $37.70 | 2021-2022 | |
| Legend Biotech USA INC. | $33.77 | 2025 | Carvykti |
| Beone Medicines USA, INC. | $29.89 | 2025 | Brukinsa |
| Sumitomo Pharma America, INC. | $21.63 | 2023 | Orgovyx |
| Karyopharm Therapeutics INC. | $21.26 | 2023 | Xpovio |
| Aveo Pharmaceuticals, INC. | $20.91 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $16.10 | 2023 | Imbruvica |
| Cumberland Pharmaceuticals, INC. | $15.72 | 2024 | Sancuso |
| Jazz Pharmaceuticals INC. | $15.35 | 2022 | |
| Mirati Therapeutics, INC. | $13.93 | 2023 | Krazati |
| Janssen Pharmaceuticals, INC | $13.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Goins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.